Brandon J Sonn1,2,3, Jessica L Saben4,5, Glenn McWilliams1, Shelby K Shelton1, Hania K Flaten1, Angelo D'Alessandro6, Andrew A Monte1,2,3,7. 1. Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7th Floor Campus Box B-215, 12401 E. 17th Avenue, Aurora, CO, 80045, USA. 2. Center for Bioinformatics & Personalized Medicine, University of Colorado School of Medicine, Aurora, CO, USA. 3. Skaggs School of Pharmacy, University of Colorado, Aurora, CO, USA. 4. Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7th Floor Campus Box B-215, 12401 E. 17th Avenue, Aurora, CO, 80045, USA. jessica.saben@cuanschutz.edu. 5. Emergency Department, University of Colorado - Anschutz Medical Campus, Building 400, Q09-127,12469 E 17th Pl, 80045, Aurora, CO, USA. jessica.saben@cuanschutz.edu. 6. Department of Structural Biology and Biochemistry, Metabolomics Core, University of Colorado Anschutz Campus, Aurora, CO, USA. 7. Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority, Denver, CO, USA.
Abstract
INTRODUCTION: Only ~ 50% of hypertensive patients will respond to treatment. OBJECTIVE: This pilot study aims to identify clinical and metabolite markers that predict response to lisinopril. METHODS: Hypertensive patients (n = 45) received lisinopril (10 mg) at their baseline visit. Blood pressures were reevaluated one week later. Responders to lisinopril (n = 19) were defined by a 10% decline in systolic blood pressure. Plasma metabolites were evaluated with mass spectrometry. RESULTS: BMI (p = 0.009), GFR (p = 0.015) and 2-oxoglutarate were included in a logistic regression model to predict response to lisinopril. CONCLUSIONS: Further validation cohorts are needed to confirm the predictive values of these clinical and metabolic markers.
INTRODUCTION: Only ~ 50% of hypertensivepatients will respond to treatment. OBJECTIVE: This pilot study aims to identify clinical and metabolite markers that predict response to lisinopril. METHODS:Hypertensivepatients (n = 45) received lisinopril (10 mg) at their baseline visit. Blood pressures were reevaluated one week later. Responders to lisinopril (n = 19) were defined by a 10% decline in systolic blood pressure. Plasma metabolites were evaluated with mass spectrometry. RESULTS: BMI (p = 0.009), GFR (p = 0.015) and 2-oxoglutarate were included in a logistic regression model to predict response to lisinopril. CONCLUSIONS: Further validation cohorts are needed to confirm the predictive values of these clinical and metabolic markers.
Entities:
Keywords:
2-Oxoglutarate; ACE/ARB; Hypertension; Lisinopril; Personalized medicine; Precision medicine
Authors: Gregory D Lewis; Laurie Farrell; Malissa J Wood; Maryann Martinovic; Zoltan Arany; Glenn C Rowe; Amanda Souza; Susan Cheng; Elizabeth L McCabe; Elaine Yang; Xu Shi; Rahul Deo; Frederick P Roth; Aarti Asnani; Eugene P Rhee; David M Systrom; Marc J Semigran; Ramachandran S Vasan; Steven A Carr; Thomas J Wang; Marc S Sabatine; Clary B Clish; Robert E Gerszten Journal: Sci Transl Med Date: 2010-05-26 Impact factor: 17.956
Authors: Stefan Offermanns; Steven L Colletti; Timothy W Lovenberg; Graeme Semple; Alan Wise; Adriaan P IJzerman Journal: Pharmacol Rev Date: 2011-03-31 Impact factor: 25.468
Authors: Michael A Puskarich; Michael A Finkel; Alla Karnovsky; Alan E Jones; Julie Trexel; Brooke N Harris; Kathleen A Stringer Journal: Ann Am Thorac Soc Date: 2015-01
Authors: R Kaddurah-Daouk; S H Boyle; W Matson; S Sharma; S Matson; H Zhu; M B Bogdanov; E Churchill; R R Krishnan; A J Rush; E Pickering; M Delnomdedieu Journal: Transl Psychiatry Date: 2011 Impact factor: 6.222
Authors: Brandon J Sonn; Kennon J Heard; Susan M Heard; Angelo D'Alessandro; Kate M Reynolds; Richard C Dart; Barry H Rumack; Andrew A Monte Journal: Clin Toxicol (Phila) Date: 2021-05-28 Impact factor: 4.467